News >

FDA Grants Pembrolizumab Priority Review for Frontline HNSCC

Gina Columbus @ginacolumbusonc
Published: Monday, Feb 11, 2019

Jonathan Cheng, MD

Jonathan Cheng, MD

The FDA has granted a priority review designation to a supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) alone or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy as a first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication